Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Celcuity (CELC – Research Report), retaining the price target of $27.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oliver McCammon has given his Buy rating due to a combination of factors, primarily focusing on the promising preliminary data from Celcuity’s ongoing clinical trials. The company’s lead drug candidate, gedatolisib, is being tested in combination with other treatments for various cancers, including metastatic castration-resistant prostate cancer (mCRPC) and HER2+ breast cancer. The early results from these trials suggest a favorable safety and efficacy profile, which is encouraging for the drug’s future development.
Additionally, the 6-month radiographic progression-free survival (rPFS) rate of 66% in the mCRPC trial is notable, especially when compared to previous studies in similar patient populations. This data, coupled with the absence of severe side effects like Grade 3 hyperglycemia and low incidence of stomatitis, supports the potential of gedatolisib as a viable treatment option. McCammon’s positive outlook is further reinforced by the anticipation of topline data from the Phase 3 VIKTORIA-1 trial, expected in Q3 2025, which could provide more comprehensive insights into the drug’s effectiveness.